Results 1 to 10 of about 58,306 (116)

Safety of COVID-19 mRNA-1273 booster doses in Asian populations: A literature review of post-marketing observational studies [PDF]

Human Vaccines & Immunotherapeutics
Real-world data on the safety of COVID-19 booster doses in Asian populations are needed to inform national immunization programs. The safety profile of mRNA-1273 (Moderna, Inc.) was evaluated using post-marketing observational data.
Chris Clarke, Daina Esposito, Veronica Urdaneta, Piyali Mukherjee, Amanda K. Buttery   +4 more
doaj   +2 more sources

Predictive modeling of immune escape and antigenic grouping of SARS-CoV-2 variants [PDF]

Journal of Virology
The ongoing adaptive evolution of Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is characterized by the continued emergence of variants with increased transmissibility and the ability to escape infection- and/or vaccine-induced immunity ...
Arshan Nasir, Diana Lee, Laura E. Avena, Daniela Montes Berrueta, Tessa Speidel, Kai Wu, Yadunanda Budigi, Andrea Carfi, Guillaume B. E. Stewart-Jones, Darin Edwards   +9 more
doaj   +2 more sources

Immune correlates analysis in NextCOVE trial for a next-generation mRNA-1283 COVID-19 vaccine [PDF]

Human Vaccines & Immunotherapeutics
SARS-CoV-2 neutralizing antibodies (nAbs) are strongly inversely associated with COVID-19 risk and have correlated with vaccine efficacy across multiple clinical trials conducted during the COVID-19 pandemic.
Chong Ma, Jing Feng, Rahnuma Wahid, Spyros Chalkias, Darin Edwards, Bethany Girard, Rituparna Das, Honghong Zhou, Lingyi Zheng   +8 more
doaj   +2 more sources

Discovery of Novel Ionizable Lipids for Lipid Nanoparticles: Lipophilicity as a Predictor of Squaramide Head Group Lipid Clearance [PDF]

Small Science
Ionizable lipids are a critical component of lipid nanoparticles (LNPs) for messenger RNA (mRNA) delivery, driving cellular uptake, endosomal escape, and tolerability.
E. Sathyajith Kumarasinghe, Edward J. Hennessy, Michael W. Danneman, Kristine E. Burke, Timothy Salerno, Erin E. Giardino, Matthew D. Crawford, Erin L. Thomas, Paulo L. Markaj, Farbod Mahmoudinobar, Edward Acosta, Carla Leite, Kerry E. Benenato, Juneyoung Lee, Mohindra Seepersaud   +14 more
doaj   +2 more sources

Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis

Nature Communications, 2023
Despite vaccine availability, influenza remains a substantial global public health concern. Here, we report interim findings on the primary and secondary objectives of the safety, reactogenicity, and humoral immunogenicity of a quadrivalent messenger RNA
Ivan T. Lee, Raffael Nachbagauer, David Ensz, Howard Schwartz, Lizbeth Carmona, Kristi Schaefers, Andrei Avanesov, Daniel Stadlbauer, Carole Henry, Ren Chen, Wenmei Huang, Daniela Ramirez Schrempp, Jintanat Ananworanich, Robert Paris   +13 more
doaj   +1 more source

Selective activation and expansion of regulatory T cells using lipid encapsulated mRNA encoding a long-acting IL-2 mutein

Nature Communications, 2022
IL-2 has been used to expand regulatory T (Treg) cells for treating inflammatory disorders. Here the authors test an engineered IL-2 mutein, delivered subcutaneously as mRNA, to show its increased specificity for activating and expanding Treg cells in ...
Seymour de Picciotto, Nicholas DeVita, Chiaowen Joyce Hsiao, Christopher Honan, Sze-Wah Tse, Mychael Nguyen, Joseph D. Ferrari, Wei Zheng, Brian T. Wipke, Eric Huang   +9 more
doaj   +1 more source

Therapeutic enzyme engineering using a generative neural network

Scientific Reports, 2022
Enhancing the potency of mRNA therapeutics is an important objective for treating rare diseases, since it may enable lower and less-frequent dosing. Enzyme engineering can increase potency of mRNA therapeutics by improving the expression, half-life, and ...
Andrew Giessel, Athanasios Dousis, Kanchana Ravichandran, Kevin Smith, Sreyoshi Sur, Iain McFadyen, Wei Zheng, Stuart Licht   +7 more
doaj   +1 more source

mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease

Nature Communications, 2021
Glycogen Storage Disease 1a (Gsd1a) is an inherited disorder caused by glucose 6-phosphatase (G6Pase-α) deficiency and characterized by hypoglycaemia and high risk of liver cancer.
Jingsong Cao, Minjung Choi, Eleonora Guadagnin, Maud Soty, Marine Silva, Vincent Verzieux, Edward Weisser, Arianna Markel, Jenny Zhuo, Shi Liang, Ling Yin, Andrea Frassetto, Anne-Renee Graham, Kristine Burke, Tatiana Ketova, Cosmin Mihai, Zach Zalinger, Becca Levy, Gilles Besin, Meredith Wolfrom, Barbara Tran, Christopher Tunkey, Erik Owen, Joe Sarkis, Athanasios Dousis, Vladimir Presnyak, Christopher Pepin, Wei Zheng, Lei Ci, Marjie Hard, Edward Miracco, Lisa Rice, Vi Nguyen, Mike Zimmer, Uma Rajarajacholan, Patrick F. Finn, Gilles Mithieux, Fabienne Rajas, Paolo G. V. Martini, Paloma H. Giangrande   +39 more
doaj   +1 more source

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19

Nature Communications, 2023
We previously presented day 29 interim safety and immunogenicity results from a phase 2/3 study (NCT04927065) comparing the Omicron-BA.1-containing bivalent vaccine mRNA-1273.214 (50-µg) to the 50-µg mRNA-1273 booster in adults who previously received ...
Spyros Chalkias, Charles Harper, Keith Vrbicky, Stephen R. Walsh, Brandon Essink, Adam Brosz, Nichole McGhee, Joanne E. Tomassini, Xing Chen, Ying Chang, Andrea Sutherland, David C. Montefiori, Bethany Girard, Darin K. Edwards, Jing Feng, Honghong Zhou, Lindsey R. Baden, Jacqueline M. Miller, Rituparna Das   +18 more
doaj   +1 more source

Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults

Human Vaccines & Immunotherapeutics, 2023
This interim analysis of an ongoing phase 1 randomized clinical trial evaluated the safety, reactogenicity, and immunogenicity of mRNA-1283, a next-generation SARS-CoV-2 messenger RNA (mRNA)-based vaccine encoding two segments of the spike protein (i.e ...
Patrick Yassini, Mark Hutchens, Yamuna D. Paila, Lorraine Schoch, Anne Aunins, Uma Siangphoe, Robert Paris   +6 more
doaj   +1 more source